Search - tctmd.com

Displaying 1 - 20 of 70

Sort: Relevancy | Date

Presentation TCT 2024

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

Presenter: Himaja Dutt Chigurupati

October 27, 2024

Presentation TCT 2024

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Kylie Duckworth

October 27, 2024

Presentation TCT 2024

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

Presenter: Nikhil Rao

October 27, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Presentation TCT 2023

TCT 528: Procedural Complications and Outcomes in Patients with Hypertrophic Obstructive Cardiomyopathy Undergoing Septal Myomectomy Versus Alcohol Septal Ablation.

Presenter: Ndausung Udongwo

October 26, 2023

Presentation TCT 2023

TCT 421: Permanent Pacemaker Following Alcohol Septal Ablation – Prevalence of Utilization at 1 Year?

Presenter: Michael Bashline

October 26, 2023

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Presentation TCT 2021

TCT 713: A Case Of Septal Reduction With Tru-Septal RF Ablation Via Coronary Sinus (TIRA) In HOCM Patient: Representative Case of The First in Man Trial Of TIRA

Presenter: Min-Ku Chon

November 04, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Presentation TCT 2019

Long-term Outcomes of Alcohol Septal Ablation

Presenter: George Hanzel

September 28, 2019

Presentation TCT 2019

Alcohol Septal Ablation Complications and Management

Presenter: Hubert Seggewiss

September 28, 2019

Presentation TCT 2019

The Alcohol Septal Ablation Procedure

Presenter: Valerian Fernandes

September 28, 2019

Presentation TCT 2019

Case Selection for Alcohol Septal Ablation

Presenter: Srihari Naidu

September 28, 2019

Presentation TCT 2019

Clinical Presentation, Pathophysiology, and Natural History

Presenter: Bernard Gersh

September 28, 2019

Presentation TCT 2019

Risk Stratification for Sudden Cardiac Death and ICD Implantation

Presenter: Bernard Gersh

September 28, 2019

Advertisement

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

TCT 528: Procedural Complications and Outcomes in Patients with Hypertrophic Obstructive Cardiomyopathy Undergoing Septal Myomectomy Versus Alcohol Septal Ablation.

TCT 421: Permanent Pacemaker Following Alcohol Septal Ablation – Prevalence of Utilization at 1 Year?

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

What’s Going to Be Hot at ACC 2022, In Person or Virtual

TCT 713: A Case Of Septal Reduction With Tru-Septal RF Ablation Via Coronary Sinus (TIRA) In HOCM Patient: Representative Case of The First in Man Trial Of TIRA

‘Enormous’ QoL Improvements With Mavacamten in HCM

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Long-term Outcomes of Alcohol Septal Ablation

Alcohol Septal Ablation Complications and Management

The Alcohol Septal Ablation Procedure

Case Selection for Alcohol Septal Ablation

Clinical Presentation, Pathophysiology, and Natural History

Risk Stratification for Sudden Cardiac Death and ICD Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content